IPM Take
Agitation in Alzheimer’s is not a side symptom. It is often the point where home care starts to break. It is fear, exhaustion, emergency calls, caregiver guilt and the painful question of whether a person can remain at home. IGC-AD1 is still investigational, and enrolment completion is not efficacy. But this milestone matters because dementia care needs better evidence for the symptoms families experience most intensely.
Executive Summary
IGC Pharma announced that its Phase 2 CALMA trial of IGC-AD1 for agitation associated with Alzheimer’s dementia reached its previously disclosed 146-patient enrolment target, with 146 participants randomized at baseline. The company said it will continue limited over-enrolment to account for attrition and support modified intent-to-treat, end-of-treatment and exploratory analyses. CALMA is a randomized, double-blind, placebo-controlled Phase 2 study evaluating IGC-AD1 in patients experiencing agitation associated with Alzheimer’s dementia. The next steps are limited over-enrolment, patient follow-up, database activities, site closeout and topline analysis.
Why it matters
- Caregivers: Agitation can turn love into crisis management. Families need options that reduce distress without simply sedating the person they are trying to protect.
- Clinicians: A Phase 2 readout could add evidence in a field where assessment, treatment and caregiver support remain uneven.
- Payers and providers: If new therapies emerge, access must come with monitoring, caregiver education and clear use criteria.
Dementia is often written about through memory. Families often live it through behaviour.
A person becomes frightened, restless, aggressive or impossible to reassure. A caregiver stops sleeping. A home becomes tense. The emergency department becomes the fallback. The decision about institutional care moves closer.
That is why agitation deserves serious coverage.
IGC Pharma’s CALMA trial has now reached its 146-patient randomized baseline target. That is not a clinical result. It is an operational milestone. But it moves the programme closer to a readout in a symptom area that has enormous human and system-level consequences.
The writing here needs to stay honest. We do not know whether IGC-AD1 works. We do know that Alzheimer’s agitation remains one of dementia care’s most difficult neuropsychiatric symptoms, and that families need more than vague reassurance.
The access question will be practical if the trial is positive. Who should receive treatment? How should agitation be assessed? What non-drug causes must be excluded first? How will clinicians avoid using medication as a shortcut for under-supported care?
For IPM, this is a dementia last-mile story. The system cannot talk only about biomarkers and disease modification while leaving families alone with the behavioural symptoms that decide whether care at home survives.bout drugs. It is about whether health systems can build the genomic operating system that makes those drugs usable.
